Sun Pharma jumps as subsidiary Taro reports healthy March quarter numbers“It is a sentiment booster for Sun Pharma. One can expect may be a 3-5 per cent uptick on the stock,” Jani said. The stock rose 4.32 per ce...
27 May, 2016, 03.45 PM IST
Sun Pharma sees biggest fall in 5 yearsThe counter witnessed one of the largest secondary market transactions when Daiichi Sankyo sold about 215 million shares in Sun Pharma via ...
22 Apr, 2015, 08.07 AM IST
Japan's Daiichi Sankyo set to sell its entire 9% stake in Sun Pharma for Rs 18,000 croreDaiichi Sankyo will exit from Sun Pharma by selling its 9% stake it owns in it for Rs 18,000 crore in block trades in the stock market.
21 Apr, 2015, 09.48 AM IST
Ranbaxy-Sun Pharma merger deal may close by 2014 end: Daiichi SankyoThe $4 billion merger deal of Ranbaxy with Sun Pharma is expected to close by the end of 2014, Japanese drug maker Daiichi Sankyo said.
11 Apr, 2014, 06.52 PM IST
Market gives a thumbs-up to Ranbaxy deal; Sun Pharma and Daiichi Sankyo gainShares of Sun Pharma surged 2.68 per cent or Rs 15.35 to close at Rs 587.25 as the all-share deal’s swap ratio is seen to favour investors ...
08 Apr, 2014, 04.26 AM IST
Ranbaxy surprises street with Q4 loss of Rs 492 croreThe Gurgaon-based firm has provisioned Rs 186 crore to deal with the costs arising out of the product recall.
27 Feb, 2013, 05.05 AM IST
Almost four years after Daiichi Sankyo's acquisition, Ranbaxy back on track with low-cost version of LipitorRanbaxy has started exporting a low-cost version of cholesterol-lowering blockbuster Lipitor to the US from its new facility in Mohali in P...
04 Apr, 2012, 04.12 AM IST
- Daiichi Sankyo reports Q3 net loss of $255 million
Daiichi Sankyo suffered a net loss of $255 million in the Octr-Dec quarter of 2011 due to a strong yen and one-time charges related to Ranb...
01 Feb, 2012, 09.27 PM IST
- Ranbaxy Laboratories may pay $500m to settle disputes in US
Ranbaxy announced a $500-million provision to resolve potential civil and criminal liabilities arising out of an investigation by the US go...
22 Dec, 2011, 07.43 AM IST
- Ranbaxy settles issue with USFDA, to pay up to USD 500 mn
Ranbaxy has reached an agreement with the US health regulator to lift a ban on import of drugs from its certain factories in India.
21 Dec, 2011, 05.42 PM IST
- Daiichi swings to profit of $43 mn in Apr-Dec period
Japanese drug maker Daiichi Sankyo today said it has swung into a profit of 39.24 billion yen (about USD 43 million) for the April-December...
29 Jan, 2010, 02.54 PM IST
- Dip in Novelis’ goodwill may hit Hindalco’s profit
Two years after its high-profile Novelis acquisition, which catapulted Hindalco to the world’s fifth-largest aluminium maker’s slot, the Ad...
17 Feb, 2009, 12.09 AM IST
- Daiichi may book non-cash loss of $3.9 bn on Ranbaxy buy in Q3
Japan’s Daiichi Sankyo, the new owner of India’s largest drugmaker Ranbaxy Laboratories, expects a non-cash valuation loss of $3.9 billion ...
06 Jan, 2009, 12.00 AM IST
- Daiichi sees $3.9 bn loss on Ranbaxy buy
Japan's Daiichi Sankyo, the new owner of India's largest drugmaker Ranbaxy Laboratories expects a non-cash valuation loss of $3.9 billion o...
05 Jan, 2009, 07.22 PM IST
- The Ranbaxy model and consolidation in pharma sector
The incipient process of consolidation in pharma sector could lead to enhanced market power & reduced competition, which in turn would rais...
24 Jun, 2008, 03.47 AM IST
- STCI Cap assigns 'underperformer' to Ranbaxy; target Rs 503
STCI Capital Markets Research has changed their recommendation to ‘underperformer’ on Ranbaxy Laboratories with a price target of Rs 503.
16 Jun, 2008, 12.29 PM IST
- Religare maintains buy on GSK Pharma, Sujana Towers
Religare Securities has maintained 'buy' on GlaxoSmithKline Pharma with a target price of Rs 1,192 based on 20 times CY09E earnings.
16 May, 2008, 03.25 PM IST